PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma

Nature Communications

Volumn 4, Issue , 2013, Pages

  Ye, Yan ^a,b   Jin, Lei ^c,d   Wilmott, James S ^c,e,f   Hu, Wang Lai ^g   Yosufi, Benafsha ^c,e,f   Thorne, Rick F ^h   Liu, Tao ⁱ   Rizos, Helen ^c,e   Yan, Xu Guang ^h   Dong, Li ^a,c   Tay, Kwang Hong ^a,c   Tseng, Hsin Yi ^a,c   Guo, Su Tang ^j   De Bock, Charles E ^h   Jiang, Chen Chen ^a,c   Wang, Chun Yan ^j   Wu, Mian ^g   Zhang, Lin Jie ^b   Hersey, Peter ^c,d   Scolyer, Richard A ^c,e,f   Zhang, Xu Dong ^a,c,j   more..

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c MELANOMA INSTITUTE AUSTRALIA   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^h UNIVERSITY OF NEWCASTLE   (Australia)

ⁱ UNIVERSITY OF NEW SOUTH WALES   (Australia)

^j SHANXI CANCER HOSPITAL   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 5 PHOSPHATASE; PROTEIN KINASE B; SYNAPTOJANIN; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ALCOHOL; CANCER; CELL ORGANELLE; DNA; ENZYME ACTIVITY; PATHOGENICITY; SIGNALING; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOCYTE; MELANOMA; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN BINDING; XENOGRAFT;

ACETYLATION; ANIMALS; CELL ADHESION; CELL EXTRACTS; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENOME, HUMAN; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOCYTES; MELANOMA; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORIC MONOESTER HYDROLASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RNA, MESSENGER; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874634909     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms2489     Document Type: Article

References (58)

1. Courtney, K. D., Corcoran, R. B. & Engelman, J. A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 28, 1075-1083 (2010)
2. Ferte, C., Andre, F. & Soria, J. C. Molecular circuits of solid tumours: prognostic and predictive tools for bedside use. Nat. Rev. Clin. Oncol. 7, 367-380 (2010)
3. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002) (Pubitemid 34716871)
4. Smalley, K. S. Understanding melanoma signaling networks as the basis for molecular targeted therapy. J. Invest. Dermatol. 130, 28-37 (2010)
5. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011)
6. Houslay, M. D. Hard times for oncogenic BRAF-expressing melanoma cells. Cancer Cell 19, 3-4 (2011)
7. Ribas, A. & Flaherty, K. T. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat. Rev. Clin. Oncol. 8, 426-433 (2011)
8. Jiang, C. C. et al. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin. Cancer Res. 17, 721-730 (2011)
9. Karreth, F. A. et al. In vivo identification of tumour-suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell 147, 382-395 (2011)
10. Paraiso, K. H. et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 71, 2750-2760 (2011)
11. Poulikakos, P. I. & Rosen, N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell 19, 11-15 (2011)
12. Cheung, M., Sharma, A., Madhunapantula, S. V. & Robertson, G. P. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res. 68, 3429-3439 (2008)
13. Dankort, D. et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41, 544-552 (2009)
14. Franke, T. F., Kaplan, D. R. & Cantley, L. C. PI3K: downstream AKTion blocks apoptosis. Cell 88, 435-437 (1997) (Pubitemid 27154408)
15. Majerus, P. W., Kisseleva, M. V. & Norris, F. A. The role of phosphatases in inositol signaling reactions. J. Biol. Chem. 274, 10669-10672 (1999)
16. Park, S. J., Itoh, T. & Takenawa, T. Phosphatidylinositol 4-phosphate 5-kinase type I is regulated through phosphorylation response by extracellular stimuli. J. Biol. Chem. 276, 4781-4787 (2001)
17. Bozulic, L. & Hemmings, B. A. PIKKing on PKB: regulation of PKB activity by phosphorylation. Curr. Opin. Cell Biol. 21, 256-261 (2009)
18. Franke, T. F. PI3K/Akt: getting it right matters. Oncogene 27, 6473-6488 (2008)
19. Gao, T., Furnari, F. & Newton, A. C. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumour growth. Mol. Cell 18, 13-24 (2005) (Pubitemid 40444644)
20. Yamada, T. et al. 3-phosphoinositide-dependent protein kinase 1, an Akt1 kinase, is involved in dephosphorylation of Thr-308 of Akt1 in Chinese hamster ovary cells. J. Biol. Chem. 276, 5339-5345 (2001)
21. Denley, A., Gymnopoulos, M., Kang, S., Mitchell, C. & Vogt, P. K. Requirement of phosphatidylinositol(3, 4, 5)trisphosphate in phosphatidylinositol 3-kinaseinduced oncogenic transformation. Mol. Cancer Res. 7, 1132-1138 (2009)
22. Gilby, D. C. et al. Gene structure, expression profiling and mutation analysis of the tumour suppressor SHIP1 in Caucasian acute myeloid leukaemia. Leukemia 21, 2390-2393 (2007) (Pubitemid 350011722)
23. Kisseleva, M. V., Cao, L. & Majerus, P. W. Phosphoinositide-specific inositol polyphosphate 5-phosphatase IV inhibits Akt/protein kinase B phosphorylation and leads to apoptotic cell death. J. Biol. Chem. 277, 6266-6272 (2002) (Pubitemid 34968418)
24. Ong, C. J. et al. Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells. Blood 110, 1942-1949 (2007) (Pubitemid 47443908)
25. Ma, K., Cheung, S. M., Marshall, A. J. & Duronio, V. PI(3, 4, 5)P3 and PI(3, 4)P2 levels correlate with PKB/akt phosphorylation at Thr308 and Ser473, respectively; PI(3, 4)P2 levels determine PKB activity. Cell Signal. 20, 684-694 (2008)
26. Carracedo, A., Alimonti, A. & Pandolfi, P. P. PTEN level in tumour suppression: how much is too little? Cancer Res. 71, 629-633 (2011)
27. Ooms, L. M. et al. The inositol polyphosphate 5-phosphatase, PIPP, is a novel regulator of phosphoinositide 3-kinase-dependent neurite elongation. Mol. Biol. Cell 17, 607-622 (2006) (Pubitemid 43191097)
28. Fedele, C. G. et al. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc. Natl Acad. Sci. USA 107, 22231-22236 (2010)
29. Gewinner, C. et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumour suppressor that inhibits PI3K signaling. Cancer Cell 16, 115-125 (2009)
30. Hodgson, M. C. et al. Decreased expression and and rogen regulation of the tumour suppressor gene INPP4B in prostate cancer. Cancer Res. 71, 572-582 (2011)
31. Franke, T. F., Kaplan, D. R., Cantley, L. C. & Toker, A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3, 4-bisphosphate. Science 275, 665-668 (1997) (Pubitemid 27061333)
32. Scheid, M. P. et al. Phosphatidylinositol (3, 4, 5)P3 is essential but not sufficient for protein kinase B (PKB) activation; phosphatidylinositol (3, 4)P2 is required for PKB phosphorylation at Ser-473: studies using cells from SH2-containing inositol-5-phosphatase knockout mice. J. Biol. Chem. 277, 9027-9035 (2002) (Pubitemid 34952976)
33. van't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002) (Pubitemid 34130608)
34. Davies, M. A. et al. Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin. Cancer Res. 15, 7538-7546 (2009)
35. Curtin, J. A., Stark, M. S., Pinkel, D., Hayward, N. K. & Bastian, B. C. PI3-kinase subunits are infrequent somatic targets in melanoma. J. Invest. Dermatol. 126, 1660-1663 (2006)
36. Curtin, J. A., Busam, K., Pinkel, D. & Bastian, B. C. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24, 4340-4346 (2006) (Pubitemid 46630793)
37. Liang, J. & Slingerland, J. M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2, 339-345 (2003)
38. Vince, J. E. et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131, 682-693 (2007) (Pubitemid 350103599)
39. Board, R. E. et al. Multiplexed assays for detection of mutations in PIK3CA. Clin. Chem. 54, 757-760 (2008) (Pubitemid 351573719)
40. Stark, M. & Hayward, N. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res. 67, 2632-2642 (2007) (Pubitemid 46548950)
41. Mirmohammadsadegh, A. et al. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res. 66, 6546-6552 (2006) (Pubitemid 44085609)
42. Bolden, J. E., Peart, M. J. & Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5, 769-784 (2006) (Pubitemid 44348499)
43. Wilson, A. J. et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J. Biol. Chem. 281, 13548-13558 (2006) (Pubitemid 43855268)
44. Kang, B. G. et al. Corepressor MMTR/DMAP1 is involved in both histone deacetylase 1-and TFIIH-mediated transcriptional repression. Mol. Cell Biol. 27, 3578-3588 (2007)
45. Marshall, G. M. et al. Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene 29, 5957-5968 (2010)
46. Lin, Y. C., Lin, J. H., Chou, C. W., Chang, Y. F., Yeh, S. H. & Chen, C. C. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. Cancer Res. 68, 2375-2383 (2008)
47. Yokota, T., Matsuzaki, Y., Miyazawa, K., Zindy, F., Roussel, M. F. & Sakai, T. Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter. Oncogene 23, 5340-53499 (2004)
48. Erneux, C., Edimo, W. E., Deneubourg, L. & Pirson, I. SHIP2 multiple functions: a balance between a negative control of PtdIns(3, 4, 5)P( ) level, a positive control of PtdIns(3, 4)P( ) production, and intrinsic docking properties. J. Cell Biochem. 112, 2203-2209 (2011)
49. Pirruccello, M. & De Camilli, P. Inositol 5-phosphatases: insights from the Lowe syndrome protein OCRL. Trends Biochem. Sci. 37, 134-143 (2012)
50. Haferkamp, S., Tran, S. L., Becker, T. M., Scurr, L. L., Kefford, R. F. & Rizos, H. The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence. Aging (Albany NY) 1, 542-556 (2009)
51. Weichert, W. et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br. J. Cancer 98, 604-610 (2008) (Pubitemid 351214528)
52. Li, L. & Davie, J. R. The role of Sp1 and Sp3 in normal and cancer cell biology. Ann. Anat. 192, 275-283 (2010)
53. Stahl, J. M. et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 64, 7002-7010 (2004) (Pubitemid 39331010)
54. Madhunapantula, S. V. & Robertson, G. P. The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res. 22, 400-419 (2009)
55. Dong, L. et al. Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress. Oncogene 30, 3716-3726 (2011)
56. Jin, L. et al. MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proc. Natl Acad. Sci. USA 108, 15840-15845 (2011)
57. Nguyen, T., Zhang, X. D. & Hersey, P. Relative resistance of fresh isolates of melanoma to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Clin. Cancer Res. 7, 966s-973s (2001) (Pubitemid 33600952)
58. Zhuang, L. et al. Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma. Histopathology 54, 462-470 (2009).